Citation Report
List of articles citing

Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment

DOI: 10.1111/j.1365-3164.2008.00694.x
Veterinary Dermatology, 2008, 19, 321-39.

Source: https://exaly.com/paper-pdf/43734129/citation-report.pdf
Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
141	Immunohistochemical evaluation of prostaglandin E2 and vascular endothelial growth factor in canine cutaneous mast cell tumours. **2010**, 8, 23-7		9
140	Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines. **2010**, 137, 208-16		18
139	Leading the way: canine models of genomics and disease. **2010**, 3, 27-34		114
138	Penile amputation and scrotal urethrostomy in 18 dogs. **2011**, 169, 657		15
137	Targeted knockdown of canine KIT (stem cell factor receptor) using RNA interference. **2011**, 141, 151-6		
136	□a□-FDG and □□C-MET positron emission tomography findings of cutaneous mast cell tumor in a dog. **2011**, 73, 355-9		1
135	Screening of therapeutic targets for canine mast cell tumors from a variety of kinase molecules. **2011**, 73, 1295-302		5
134	Canine conjunctival mast cell tumors: a retrospective study. **2011**, 14, 153-60		23
133	Canine mammary tumours, an overview. **2011**, 46, 1112-31		105
132	Mast cell tumour and cutaneous histiocytoma excision wound healing in general practice. **2011**, 52, 469-75		6
131	Prognostic markers for myeloid neoplasms: a comparative review of the literature and goals for future investigation. *Veterinary Pathology*, **2011**, 48, 182-97	2.8	22
130	Canine Cutaneous Mast Cell Tumor: Biologic Behavior and Its Correlation with Prognostic Indicators. **2012**, 02, 255-261		4
129	c-KIT messenger RNA and protein expression and mutations in canine cutaneous mast cell tumors: correlations with post-surgical prognosis. *Journal of Veterinary Diagnostic Investigation*, **2012**, 24, 116-26	1.5	31
128	European consensus document on mast cell tumours in dogs and cats. **2012**, 10, e1-e29		127
127	Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics. **2012**, 137, 197-205		37
126	Differences in the proteome of high-grade versus low-grade canine cutaneous mast cell tumours. **2012**, 194, 210-4		19
125	Cutaneous mast cell tumor and mastocytosis in a black-masked lovebird (Agapornis personata). **2012**, 26, 29-35		10

124	A multicancer-like syndrome in a dog characterized by p53 and cell cycle-checkpoint kinase 2 (CHK2) mutations and sirtuin gene (SIRT1) down-regulation. *Research in Veterinary Science*, **2012**, 93, 240-5	2.5	6
123	Immunohistochemical evaluation of AKT protein activation in canine mast cell tumours. **2012**, 147, 171-6		6
122	Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinases and vascular endothelial growth factor in canine mast cell tumours. **2012**, 147, 419-29		31
121	Biological effect of tyrosine kinase inhibitors on three canine mast cell tumor cell lines with various KIT statuses. **2012**, 35, 97-104		11
120	Evaluation of cyclooxygenase-2 expression in canine mast cell tumours. **2012**, 147, 31-6		8
119	A novel imaging system permits real-time in vivo tumor bed assessment after resection of naturally occurring sarcomas in dogs. **2013**, 471, 834-42		31
118	Stomach. **2013**, 606-650		
117	Heterogeneity of internal tandem duplications in the c-kit of dogs with multiple mast cell tumours. **2013**, 54, 377-80		11
116	Pathology in practice. Mast cell tumor (MCT) of the oral mucosa with submandibular lymph node metastasis in a dog. *Journal of the American Veterinary Medical Association*, **2013**, 243, 795-7	1	2
115	Simultaneous quantification of vinblastine and desacetylvinblastine concentrations in canine plasma and urine samples using LC-APCI-MS/MS. **2013**, 913-914, 147-54		9
114	Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: a retrospective cohort study. **2013**, 196, 492-8		48
113	Evaluation of prognostic indicators in dogs with multiple, simultaneously occurring cutaneous mast cell tumours: 63 cases. **2013**, 11, 51-62		27
112	Rapid Evaluation of Mutant Exon-11 inc-kitin a Recurrent MCT Case Using CD117 Immunocytofluorescence, FACS-Cell Sorting, and PCR. **2013**, 2013, 1-4		1
111	Expression of Ki67, BCL-2, and COX-2 in canine cutaneous mast cell tumors: association with grading and prognosis. *Veterinary Pathology*, **2013**, 50, 110-21	2.8	53
110	Relação da expressão de fatores de crescimento celular (IGF-1) e (SCF) com fatores prognósticos e o alvo da rapamicina em mamíferos (m-TOR) em mastocitomas cutâneos caninos. *Pesquisa Veterinaria Brasileira*, **2013**, 33, 549-556	0.4	2
109	Análise de sobrevida e fatores prognósticos de cães com mastocitoma cutâneo. *Pesquisa Veterinaria Brasileira*, **2014**, 34, 874-884	0.4	1
108	Cutaneous mast cell tumor (Mastocytoma): cyto- histopathological and haematological investigations. **2014**, 9, 9		8
107	Reproducibility of nuclear morphometry parameters from cytologic smears of canine cutaneous mast cell tumors--intra- and interobserver variability. *Veterinary Clinical Pathology*, **2014**, 43, 469-72	1	9

106	The Relevance of CD117-Immunocytochemistry Staining Patterns to Mutational Exon-11 in c-kit Detected by PCR from Fine-Needle Aspirated Canine Mast Cell Tumor Cells. **2014**, 2014, 787498		13
105	Incorporation of sentinel lymph node mapping in dogs with mast cell tumours: 20 consecutive procedures. **2014**, 12, 215-26		68
104	Recombinant canine IgE Fc and an IgE Fc-TRAIL fusion protein bind to neoplastic canine mast cells. **2014**, 159, 29-40		2
103	Systemic mastocytosis in an African fat-tail gecko (Hemitheconyx caudicinctus). **2014**, 151, 130-4		7
102	Breed related odds ratio and anatomic distribution of canine mast cell tumours in Austria. Retrospective study of cases in the years 2000-2010. **2014**, 42, 367-73		8
101	Morphological Features and KIT Receptor Expression in Canine Cutaneous Mast Cell Tumor and Systemic Mastocytosis / Morfolo e Karakteristike I Ekspresija KIT Receptora Kod Kutanih Mastocitoma I Sistemske Mastocitoze Pasa. **2015**, 65, 226-237		1
100	Identification of additional mitochondrial DNA mutations in canine mast cell tumours. **2016**, 58, 28		8
99	Current perspectives on the optimal age to spay/castrate dogs and cats. **2015**, 6, 171-180		14
98	Diagnostic procedures for improving of the KIT (CD117) expressed allele burden for the liver metastases from uterus mast cell tumors: prognostic value of the metastatic pattern and tumor biology. **2015**, 36, 929-37		4
97	In vivo model for mastocytosis: A comparative review. **2015**, 93, 159-69		9
96	CD72 negatively regulates mouse mast cell functions and down-regulates the expression of KIT and FcRI **2015**, 27, 95-103		6
95	p62/Sequestosome-1: Mapping Sites of Protein-Handling Stress in Canine Cutaneous Mast Cell Tumors. *Veterinary Pathology*, **2015**, 52, 621-30	2.8	4
94	Biology and Diseases of Dogs. **2015**, 511-554		2
93	Management of an anaphylactoid crisis due to mast cell degranulation in a dog during general anaesthesia. **2015**, 3, e000177		2
92	Prevalence and risk factors for mast cell tumours in dogs in England. **2015**, 2, 1		51
91	Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours. **2015**, 13, 314-21		16
90	Clinical, Cytological, Histological and Immunohistochemical Features of Cutaneous Mast Cell Tumours in Ferrets (Mustela putorius furo). **2016**, 155, 346-355		7
89	Skin Tumors. **2016**, 59-97		0

88	Kit Receptor Expression in Canine Cutaneous Mast Cell Tumors (CMCTs) Without C-Kit Mutation. **2016**, 66, 222-233		1
87	Application of post-genomic techniques in dog cancer research. **2016**, 12, 2665-79		5
86	Receptor Tyrosine Kinase Expression Profiles in Canine Cutaneous and Subcutaneous Mast Cell Tumors. *Veterinary Pathology*, **2016**, 53, 545-58	2.8	18
85	Increased expression of tissue inhibitor of metalloproteinase-1 correlates with improved outcome in canine cutaneous mast cell tumours. **2017**, 15, 606-614		8
84	Association of breed and histopathological grade in canine mast cell tumours. **2017**, 15, 829-839		25
83	Skin depigmentation associated with toceranib phosphate in a dog. *Veterinary Dermatology*, **2017**, 28, 400-e95	1.8	7
82	The Effect of CoMnFeO Ferrite Nanoparticles on the C2 Canine Mastocytoma Cell Line and Adipose-Derived Mesenchymal Stromal Stem Cells (ASCs) Cultured Under a Static Magnetic Field: Possible Implications in the Treatment of Dog Mastocytoma. **2017**, 10, 209-222		6
81	Skin diseases of juvenile cats and dogs. **2017**, 22, 574-585		
80	Antihistaminic and cardiorespiratory effects of diphenhydramine hydrochloride in anesthetized dogs undergoing excision of mast cell tumors. *Journal of the American Veterinary Medical Association*, **2017**, 251, 804-813	1	1
79	Epidemiological Study of Canine Mast Cell Tumours According to the Histological Malignancy Grade. **2017**, 20, 455-465		8
78	Pilot assessment of vascular endothelial growth factor receptors and trafficking pathways in recurrent and metastatic canine subcutaneous mast cell tumours. *Veterinary Medicine and Science*, **2017**, 3, 146-155	2.1	8
77	Proteases as prognostic markers in human and canine cancers. **2017**, 15, 669-683		11
76	SPINAL MAST CELL TUMORS IN DOGS: IMAGING FEATURES AND CLINICAL OUTCOME OF FOUR CASES. **2017**, 58, 44-52		3
75	Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors. **2018**, 15, 129-136		5
74	Multispectral analysis tools can increase utility of RGB color images in histology. **2018**, 20,		9
73	Assessment of Canine Mast Cell Tumor Mortality Risk Based on Clinical, Histologic, Immunohistochemical, and Molecular Features. *Veterinary Pathology*, **2018**, 55, 212-223	2.8	39
72	The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma. **2018**, 16, 55-68		13
71	Apoptotic intrinsic pathway proteins predict survival in canine cutaneous mast cell tumours. **2018**, 16, E38-E44		5

70	Diagnostic accuracy of pre-treatment biopsy for grading cutaneous mast cell tumours in dogs. **2018**, 16, 214-219		10
69	Mastocitoma cutâneo canino: estudo retrospectivo dos casos atendidos pelo Serviço de Oncologia do Hospital Veterinário da FCAV-Unesp, Campus Jaboticabal, de 2005 a 2015. *Pesquisa Veterinaria Brasileira*, **2018**, 38, 1808-1817	0.4	2
68	Hematopoietic Neoplasia. **2018**, 363-395		
67	Epidemiological assessment of the risk of canine mast cell tumours based on the Kiupel two-grade malignancy classification. **2018**, 60, 70		12
66	Identification of molecular genetic contributants to canine cutaneous mast cell tumour metastasis by global gene expression analysis. *PLoS ONE*, **2018**, 13, e0208026	3.7	5
65	Acute radiotherapy toxicity in 57 dogs with gross and microscopic mast cell tumours. **2018**, 16, 431-440		1
64	Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study). *Frontiers in Veterinary Science*, **2018**, 5, 116	3.1	9
63	Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms. **2019**, 17, 1-10		11
62	Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells. **2019**, 17, 553-561		9
61	Erythematous Wheals and Angioedema. **2019**, 181-195		
60	Skin Nodules and Tumors. **2019**, 221-238		
59	Intratumoral collagen index predicts mortality and survival in canine cutaneous mast cell tumours. *Veterinary Dermatology*, **2019**, 30, 162-e48	1.8	1
58	Presumptive primary intrathoracic mast cell tumours in two dogs. **2019**, 15, 204		5
57	Fine-needle aspiration of cutaneous, subcutaneous, and intracavitary masses in dogs and cats using 22- vs 25-gauge needles. *Veterinary Clinical Pathology*, **2019**, 48, 287-292	1	4
56	Identification of two molecular subtypes in canine mast cell tumours through gene expression profiling. *PLoS ONE*, **2019**, 14, e0217343	3.7	5
55	A synonymous germline variant in a gene encoding a cell adhesion molecule is associated with cutaneous mast cell tumour development in Labrador and Golden Retrievers. **2019**, 15, e1007967		5
54	Patient and tumour factors influencing canine mast cell tumour histological grade and mitotic index. **2019**, 17, 338-344		3
53	Heteroplasmic Mutations and Polymorphisms in the Gene of Mitochondrial DNA in Canine Mast Cell Tumours. **2019**, 33, 57-63		3

52	Occurrence and Distribution of Canine Cutaneous Mast Cell Tumour Characteristics Among Predisposed Breeds. **2019**, 63, 141-148		5
51	Abdominal CT evaluation of the liver and spleen for staging mast cell tumors in dogs yields nonspecific results. **2019**, 60, 306-315		5
50	Morphological and molecular identification of Acanthocheilonema reconditum in a canine. **2019**, 28, 271-274		4
49	Structural and copy number chromosome abnormalities in canine cutaneous mast cell tumours. **2019**, 60, 63-70		2
48	Mutation and methylation status of KIT and TP in canine cutaneous and subcutaneous mast cell tumours. **2020**, 18, 438-444		3
47	Canine and Feline Cutaneous Mast Cell Tumor: A Comprehensive Review of Treatments and Outcomes. *Topics in Companion Animal Medicine*, **2020**, 41, 100472	1.1	3
46	Sentinel lymph node detection differs when comparing lymphoscintigraphy to lymphography using water soluble iodinated contrast medium and digital radiography in dogs. **2020**, 61, 659-666		0
45	Characterization of skin surface and dermal microbiota in dogs with mast cell tumor. **2020**, 10, 12634		2
44	Mast cell tumours in dogs less than 12 months of age: a multi-institutional retrospective study. **2020**, 61, 449-457		0
43	miRNA profiles of canine cutaneous mast cell tumours with early nodal metastasis and evaluation as potential biomarkers. **2020**, 10, 18918		1
42	Successful long-term management with toceranib phosphate of a recurrent muzzle mast cell tumour in a´dog. **2020**, 65, 227-232		1
41	The effect of surgery on lymphoscintigraphy drainage patterns from the canine brachium in a simulated tumor model. *Veterinary Surgery*, **2020**, 49, 1118-1124	1.7	2
40	Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46). *Journal of Veterinary Internal Medicine*, **2021**, 35, 415-429	3.1	17
39	Systemic mastocytosis with subcutaneous hemorrhage and edema in a Greyhound dog: case report and review of diagnostic criteria. *Journal of Veterinary Diagnostic Investigation*, **2021**, 33, 95-100	1.5	0
38	In vitro effects of histamine receptor 1 antagonists on proliferation and histamine release in canine neoplastic mast cells. *Veterinary Medicine and Science*, **2021**, 7, 57-68	2.1	3
37	Prevalence of pulmonary nodules suggestive of metastasis at presentation in dogs with cutaneous or subcutaneous soft tissue sarcoma. *Journal of the American Veterinary Medical Association*, **2021**, 258, 179-185	1	0
36	Outcome of dogs with intermediate grade low mitotic index high Ki67 mast cell tumours treated with surgery and single agent lomustine. *Australian Veterinary Journal*, **2021**, 99, 146-151	1.2	
35	RNAScope Hybridization as a Novel Technique for the Assessment of c-KIT mRNA Expression in Canine Mast Cell Tumor. *Frontiers in Veterinary Science*, **2021**, 8, 591961	3.1	0

34	Immunohistochemical Expression of Vascular Endothelial Growth Factor as a Prognostic Marker for Canine Mast Cell Tumors. *Topics in Companion Animal Medicine*, **2021**, 42, 100506	1.1	1
33	Galectin-3 immunolabelling correlates with BCL2 expression in canine cutaneous mast cell tumours. *Acta Veterinaria Hungarica*, **2021**, 69, 169-174	1	
32	Intratumoural Treatment of 18 Cytologically Diagnosed Canine High-Grade Mast Cell Tumours With Tigilanol Tiglate. *Frontiers in Veterinary Science*, **2021**, 8, 675804	3.1	0
31	Beclin-1 is a novel predictive biomarker for canine cutaneous and subcutaneous mast cell tumors. *Veterinary Pathology*, **2021**, 3009858211042578	2.8	
30	Electrochemotherapy in veterinary oncology: from rescue to first line therapy. *Methods in Molecular Biology*, **2014**, 1121, 247-56	1.4	19
29	Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade. *PLoS ONE*, **2014**, 9, e98415	3.7	66
28	Sequencing and G-quadruplex folding of the canine proto-oncogene KIT promoter region: might dog be used as a model for human disease?. *PLoS ONE*, **2014**, 9, e103876	3.7	16
27	Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma. *PLoS ONE*, **2016**, 11, e0157176	3.7	54
26	Immunohistochemical and molecular profiling of CD 117, Oct-4, and Sox-2 in canine cutaneous mast cell tumor of the crossbred dogs in Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand.. *Veterinary World*, **2021**, 14, 2646-2654	1.7	
25	Cytology of Skin Tumours. **2017**, 291-490		0
24	Heat Shock Protein Expression and Implications in Spontaneous Animal Tumors: Veterinary and Comparative Aspects. *Heat Shock Proteins*, **2017**, 81-101	0.2	
23	Hauttumoren. **2017**, 57-95		
22	Study of the Connection Between Autoinflammatory Disease and the Development of a Mast Cell Tumor on the Example of Shar-Pei. *Bulletin of Science and Practice*, **2019**, 5, 232-239	0.2	
21	Canine cutaneous neoplasms in the metropolitan region of Goiânia, Goiás state, Brazil. *Pesquisa Veterinaria Brasileira*, **2020**, 40, 614-620	0.4	
20	Characterization of canine mastocytoma cell response to cryoablation. *International Journal of Veterinary Science and Research*, **2020**, 6, 005-013	0.3	
19	Defect in Mitochondrial NADH-Dehydrogenase Genes in Canine Mast Cell Tumours. *Annals of Animal Science*, **2020**, 20, 919-937	2	1
18	Urticaria pigmentosa-like disease in a dog. *Canadian Veterinary Journal*, **2015**, 56, 245-8	0.5	6
17	Presumptive primary pulmonary mast cell tumor in 2 dogs. *Canadian Veterinary Journal*, **2017**, 58, 591-596	0.5	5

16	Intranasal mast cell tumor in the dog: A case series. *Canadian Veterinary Journal*, **2017**, 58, 851-854	0.5	3
15	Intramuscular mast cell tumors in 7 dogs. *Canadian Veterinary Journal*, **2017**, 58, 931-935	0.5	2
14	The effect of prednisone on histologic and gross characteristics in canine mast cell tumors. *Canadian Veterinary Journal*, **2021**, 62, 45-50	0.5	0
13	Analysis of risk factors for canine mast cell tumors based on the Kiupel and Patnaik grading system among dogs with skin tumors.. *Open Veterinary Journal*, **2021**, 11, 619-634	1	0
12	Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors.. *Cells*, **2022**, 11,	7.9	4
11	Tigilanol Tiglate-Mediated Margins: A Comparison With Surgical Margins in Successful Treatment of Canine Mast Cell Tumours.. *Frontiers in Veterinary Science*, **2021**, 8, 764800	3.1	1
10	Inclusion of fibroblasts and collagen fibrils in the cytologic grading of canine cutaneous mast cell tumors.. *Veterinary Clinical Pathology*, **2022**,	1	2
9	The Effect of Opioid Administration on Cytologic and Histopathologic Diagnosis of Canine Cutaneous Mast Cell Tumors Treated by Surgical Excision. *Veterinary Sciences*, **2022**, 9, 202	2.4	0
8	Exploring the association of intratumoral immune cell infiltrates with histopathologic grade in canine mast cell tumors.. *Research in Veterinary Science*, **2022**, 147, 83-91	2.5	0
7	Intranasal mast cell tumors: Clinical, immunohistochemical, and molecular features in 20 dogs. *Veterinary Pathology*, 030098582211091	2.8	
6	Activating Mutation in the Receptor Tyrosine Kinase FLT3 with Clinicopathological Relevance in Canine Mast Cell Tumors. **2022**, 2022, 1-10		0
5	Salivary miR-21 is a potential biomarker for canine mast cell tumors. 030098582211289		0
4	Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate. 9,		0
3	Mutations of the c-KIT gene in canine mast cell tumors and respective nodal metastases classified according to mast cell infiltration. 43,		0
2	Prognostic value of epigenetic markers for canine mast cell cancer. **2023**, 18, e0283616		0
1	Cytological grading of canine mast cell tumors: correlation with histologic grading and survival time. 43,		0